vTv Therapeutics (VTVT) Net Cash Flow (2014 - 2026)

vTv Therapeutics has disclosed Net Cash Flow across 13 years of filings, most recently posting -$11.4 million for Q2 2026.

• In Q2 2026, Net Cash Flow fell 122.76% year-over-year to -$11.4 million; the TTM figure through Jun 2026 stood at $60.7 million (up 409.74% YoY), while the FY2025 annual figure was $52.2 million, up 91.16% from the prior year.
• Net Cash Flow came in at -$11.4 million for Q2 2026 at vTv Therapeutics, down from $9.2 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $72.6 million in Q3 2025 to a low of -$11.4 million in Q2 2026.
• Average Net Cash Flow over 5 years is $4.1 million, with a median of -$3.6 million recorded in 2022.
• Year-over-year, Net Cash Flow tumbled 499.42% in 2024 and surged 1935.2% in 2025.
• Over 5 years, Net Cash Flow stood at -$3.2 million in 2022, then soared by 137.6% to $1.2 million in 2023, then plunged by 499.42% to -$4.8 million in 2024, then sank by 98.38% to -$9.6 million in 2025, then decreased by 19.55% to -$11.4 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were -$11.4 million in Q2 2026, $9.2 million in Q1 2026, and -$9.6 million in Q4 2025.